Company: CRVO
Filing Date: 2025-05-12
Form Type: 424B5
Source: 0001437749-25-016167
Chunk: 9

Company: CervoMed Inc.
Filing Date: 2025-05-12
Form: 424B5
Chunk 9
---
.

<div align='center'>S-5

RISK FACTORS</div>

Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described below and in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings with the SEC, each of which are incorporated by reference in this prospectus supplement, and all of the other information in this prospectus supplement, including our financial statements and related notes incorporated by reference herein. If any of these risks is realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties that are not yet identified or that we currently believe to be immaterial may also materially harm our business, financial condition, results of operations and prospects and could result in a complete loss of your investment.

Risks Related to This Offering and Our Common Stock

If you purchase common stock in this offering, you may incur immediate dilution of your investment.

The public offering price of our common stock may exceed the net tangible book value per share of our common stock. Assuming that an aggregate of 5,889,281 shares of common stock are sold at a price of $8.49 per share, the last reported sale price of our common stock on The NASDAQ Capital Market on May 9, 2025, for aggregate gross proceeds of approximately $50,000,000, and after deducting estimated offering commissions and offering expenses payable by us, you would experience immediate dilution of $2.86per share, representing the difference between our as adjusted net tangible book value per share as of March 31, 2025 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options and the exercise of warrants would result in further dilution of your investment. See the section below titled “Dilution” for a more detailed illustration of the dilution you will incur if you participate in this offering. Because the sales of the shares offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing stockholders, will experience significant dilution if we sell shares